These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 17853928

  • 1. Is it time to stop treating dyslipidaemia with fibrates?
    Benatar JR, Stewart RA.
    N Z Med J; 2007 Sep 07; 120(1261):U2706. PubMed ID: 17853928
    [Abstract] [Full Text] [Related]

  • 2. Role for fibrate therapy in diabetes: evidence before FIELD.
    Vergès B.
    Curr Opin Lipidol; 2005 Dec 07; 16(6):648-51. PubMed ID: 16276243
    [Abstract] [Full Text] [Related]

  • 3. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
    Allemann S, Diem P, Egger M, Christ ER, Stettler C.
    Curr Med Res Opin; 2006 Mar 07; 22(3):617-23. PubMed ID: 16574044
    [Abstract] [Full Text] [Related]

  • 4. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P, Attvall S, Nilsson PM.
    Lakartidningen; 2006 Mar 07; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract] [Full Text] [Related]

  • 5. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
    Wierzbicki AS.
    Diabetes Obes Metab; 2009 Mar 07; 11(3):261-70. PubMed ID: 17645560
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH.
    Am J Cardiol; 2007 Feb 19; 99(4A):133B-140B. PubMed ID: 17307065
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B, Maes M, Zambon A.
    Nat Clin Pract Cardiovasc Med; 2008 Sep 19; 5(9):542-53. PubMed ID: 18628776
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?
    Taskinen MR.
    Nutr Metab Cardiovasc Dis; 2006 Dec 19; 16(8):509-12. PubMed ID: 17071064
    [No Abstract] [Full Text] [Related]

  • 14. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.
    Eur J Intern Med; 2009 Mar 19; 20(2):197-200. PubMed ID: 19327612
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
    Davidson MH.
    Am J Cardiol; 2005 Nov 07; 96(9A):3K-13K; discussion 34K-35K. PubMed ID: 16291008
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A.
    Diabetes Metab Res Rev; 2008 Nov 07; 24(4):286-93. PubMed ID: 18273835
    [Abstract] [Full Text] [Related]

  • 20. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
    Turhan H, Yetkin E.
    Int J Cardiol; 2006 Jun 16; 110(2):276-7. PubMed ID: 16364471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.